November 1, 2023
2 minutes viewing
VANCOUVER, British Columbia — In this Healio exclusive video, Dr. Nesrine B. Augustine, She reviewed a case of a patient with ulcerative colitis and associated SARS-CoV-2 infection, which she presented at the ACG Annual Scientific Meeting.
“This is a very important case because there are many different specialties involved, including infectious diseases, gastroenterology, and of course hospitalists,” said Augustine, an internist at Tift Regional Medical Center in Georgia. He told Helio.
A 53-year-old Caucasian woman with a history of morbid obesity and ulcerative colitis presented with what appeared to be an acute flare-up, including abdominal pain, bloody diarrhea, nausea, vomiting, and more than 25 bowel movements per day for 3 days, according to Dr. Augustine. He is said to have developed symptoms. day to day. The patient tested positive for SARS-CoV-2.
“It certainly brought up a lot of different questions, because as we know, many of the drugs we use for ulcerative colitis tend to affect the immune system,” Augustin he said. “As you know, COVID-19 has affected our bodies in many ways, and there are still many questions that need to be answered.”
The patient was treated with supportive care, including intravenous fluid and electrolyte replacement, and intravenous methylprednisolone, ciprofloxacin, and metronidazole. Rectal mesalamine was added to her treatment plan, leading to some improvement, but she later relapsed.
According to Dr. Augustin, the patient started alternating treatment with infliximab and cyclosporine, and although he initially had some response to infliximab, the patient relapsed and underwent colectomy.
“I think this case highlights the need to be aware of the differences that COVID-19 presents in treating patients with ulcerative colitis,” Augustine said.
Information source/disclosure information
Augustine NB. Severe acute ulcerative colitis with SARS-CoV-2 infection: a case report
Presentation location: ACG Annual Academic Conference; October 20-25, 2023. Vancouver, British Columbia (hybrid conference).
Augustine does not report any relevant financial disclosures.